RCS - Creo Medical Group - Opening of Singapore regional hub

Creo MedicalAnnouncement

20/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220420:nRST6573Ia&default-theme=true

RNS Number : 6573I  Creo Medical Group PLC  20 April 2022

REACH

Creo Medical Group plc

("Creo" or the "Company")

 

Creo opens Singapore regional hub

 

Commercial hub further strengthens Creo's footprint across Asia-Pacific region

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that it has officially opened
its regional hub in Singapore, with the first-class facility providing a
multi-functional centre for the commercial roll-out of Creo's products across
the Asia-Pacific ("APAC") region.

 

The facility will provide a base for Creo's staff working across the region
and includes a training centre, demonstration room, service centre and
conference room.

 

The regional commercial hub also forms a key part of Creo's international
strategy - providing a direct sales and marketing presence across APAC and
will be central to the management of Creo's distribution partners in the APAC
region. During the COVID-19 pandemic Creo has carefully selected and engaged
with a number of distribution partners in the region including in South Korea,
Hong Kong, Vietnam, Thailand, Malaysia, Indonesia, India, Sri Lanka and
Australia. The hub will support these partners as they start to satisfy the
backlog of demand in their markets as they emerge from the COVID-19 pandemic.

 

In addition, this carefully designed hub aims to accelerate ongoing technology
and product development, with local innovation centres and universities
already expressing interest in collaborating and partnering. The site also
allows the Company to better target and engage with potential users across the
region and more broadly showcase Creo's core technology and products to new
markets.

 

A number of prominent KOLs were invited to attend the opening and meet the
Creo team to discuss the benefits of Creo's innovative range of advanced
energy devices. One such KOL, Clinical Assistant Professor Damien Tan,
Director, Endoscopy Centre, Singapore General Hospital, Singapore, said
"Creo's opening brings the latest cutting-edge technology in endoscopy to
Singapore and the region. We are proud and excited to be able to work with
this new and exciting technology."

 

Craig Gulliford, Chief Executive Officer of Creo, said: "It's fantastic to see
this regional hub officially open - it's a first-rate facility which allows
Creo to build on the important groundwork already done as we step up and roll
out our products to new and exciting audiences and markets.

 

"The demand is clear from the engagement we've already had, and this
commercial hub is a key cog in turning that demand into users and, ultimately,
better outcomes for patients across APAC, whilst helping to deliver on our
'Build, Buy and Partner' strategy."

 

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

Enquiries:

 

 Creo Medical Group plc                              www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                  +44 (0)1291 606 005

 Cenkos Securities plc                               +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)             +44 (0)20 7260 1000

 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                     Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUKUNRUWUSAAR